Jeff Michalski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7450581/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiotherapy and Oncology, 2018, 126, 519-526.	0.6	320
2	Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: DosimetricÂand Clinical Effects of Perirectal Spacer Application in Men Undergoing ProstateÂlmage Guided Intensity Modulated RadiationÂTherapy. International Journal of Radiation Oncology Biology Physics, 2015, 92, 971-977.	0.8	285
3	Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results ofÂaÂPhase III Trial. International Journal of Radiation Oncology Biology Physics, 2017, 97, 976-985.	0.8	276
4	Online Magnetic Resonance Image Guided Adaptive Radiation Therapy: First Clinical Applications. International Journal of Radiation Oncology Biology Physics, 2016, 94, 394-403.	0.8	245
5	Minimally Important Difference for the Expanded Prostate Cancer Index Composite Short Form. Urology, 2015, 85, 101-106.	1.0	241
6	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. International Journal of Radiation Oncology Biology Physics, 2018, 101, 152-168.	0.8	138
7	Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial. Advances in Radiation Oncology, 2019, 4, 201-209.	1.2	133
8	Simulated Online Adaptive Magnetic Resonance–Guided Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Disease of the Abdomen and Central Thorax: Characterization of Potential Advantages. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1078-1086.	0.8	113
9	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 2685-2697.	1.6	91
10	Quality of Intensity Modulated Radiation Therapy Treatment Plans Using a 60 Co Magnetic Resonance Image Guidance Radiation Therapy System. International Journal of Radiation Oncology Biology Physics, 2015, 92, 771-778.	0.8	69
11	Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall. Practical Radiation Oncology, 2017, 7, 195-202.	2.1	62
12	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	7.1	61
13	Clinical Outcome of Patients Treated With 3D Conformal Radiation Therapy (3D-CRT) for Prostate Cancer on RTOG 9406. International Journal of Radiation Oncology Biology Physics, 2012, 83, e363-e370.	0.8	58
14	Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 2018, 8, e7-e15.	2.1	43
15	Radiation exposure to family and household members after prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2003, 56, 764-768.	0.8	38
16	Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database. Journal of Urology, 2018, 199, 416-423.	0.4	36
17	Errors in Radiation Oncology: A Study in Pathways and Dosimetric Impact. Journal of Applied Clinical Medical Physics, 2005, 6, 81-94.	1.9	26
18	Satisfaction with Information Used to Choose Prostate Cancer Treatment. Journal of Urology, 2014, 191, 1265-1271.	0.4	23

JEFF MICHALSKI

#	Article	IF	CITATIONS
19	The world's first single-room proton therapy facility: Two-year experience. Practical Radiation Oncology, 2017, 7, e71-e76.	2.1	21
20	Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors. Advances in Radiation Oncology, 2021, 6, 100639.	1.2	21
21	Report dose-to-medium in clinical trials where available; a consensus from the Global Harmonisation Group to maximize consistency. Radiotherapy and Oncology, 2021, 159, 106-111.	0.6	21
22	Low incidence of new biochemical hypogonadism after intensity modulated radiation therapy for prostate cancer. Practical Radiation Oncology, 2014, 4, 430-436.	2.1	16
23	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. Journal of Clinical Oncology, 2022, 40, 1500-1505.	1.6	16
24	First Reported Case of Pediatric Radiation Treatment With Magnetic Resonance Image Guided Radiation Therapy. Advances in Radiation Oncology, 2019, 4, 233-236.	1.2	15
25	Intensity modulated radiation therapy and surgery for Management of Retroperitoneal Sarcomas: a single-institution experience. Radiation Oncology, 2017, 12, 198.	2.7	13
26	Who Benefits From a Prostate Rectal Spacer? Secondary Analysis of a Phase III Trial. Practical Radiation Oncology, 2020, 10, 186-194.	2.1	13
27	Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate. International Journal of Radiation Oncology Biology Physics, 2021, 110, 700-707.	0.8	13
28	18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Practical Radiation Oncology, 2020, 10, 354-362.	2.1	9
29	The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. International Journal of Radiation Oncology Biology Physics, 2018, 102, 775-782.	0.8	4
30	Radiation Therapy as Definitive Local Treatment in Patients with Limited-Stage Small Cell Carcinoma of the Bladder: Does total dose matter?. Bladder Cancer, 2018, 4, 311-317.	0.4	2
31	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. Neuro-Oncology, 2020, 22, iii391-iii391.	1.2	2
32	Counterpoint: Unfair comparisons lead to unwarranted conclusions—Can treatment modalities for localized prostate cancer truly be compared without bias?. Brachytherapy, 2015, 14, 756-760.	0.5	1
33	In Regard to Habl etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 241-242.	0.8	1
34	The Role of MRI-Guided Radiation Therapy for Palliation of Mobile Abdominal Cancers: A Report of Two Cases. Advances in Radiation Oncology, 2021, 6, 100662.	1.2	1
35	Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer. Journal of Clinical Oncology, 2021, 39, 2847-2848.	1.6	1
36	Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy. Journal of Urology, 2022, 207, 1227-1235.	0.4	1

#	Article	IF	CITATIONS
37	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. Neuro-Oncology, 2018, 20, i68-i69.	1.2	0
38	Adherence of US Insurance Payer Policies to the American Society of Radiation Oncology Stereotactic Radiosurgery Model Policy. Practical Radiation Oncology, 2020, 10, e250-e254.	2.1	0
39	MBCL-15. IMPACT OF MOLECULAR SUBGROUPS ON OUTCOMES FOLLOWING RADIATION TREATMENT RANDOMIZATIONS FOR AVERAGE RISK MEDULLOBLASTOMA: A PLANNED ANALYSIS OF CHILDREN'S ONCOLOGY GROUP (COG) ACNS0331. Neuro-Oncology, 2020, 22, iii391-iii391.	1.2	0
40	QOL-20. IMPACT OF RADIATION DOSE AND VOLUME ON MEMORY FUNCTIONING IN CHILDREN WITH MEDULLOBLASTOMA: A REPORT FROM CHILDREN'S ONCOLOGY GROUP (COG) ACNS0331. Neuro-Oncology 2020, 22, iii434-iii435.	, 1.2	0
41	Reply by Authors. Journal of Urology, 2022, , 101097JU000000000000245502.	0.4	0